Depo-Provera Meningioma Lawsuit FAQs

Depo-Provera lawsuits generally allege that women developed meningiomas after using depot medroxyprogesterone acetate injections and that they were not adequately warned about that risk soon enough. These claims focus on product liability issues such as warnings, safety monitoring, risk communication, and whether different prescribing decisions might have been made if doctors and patients had been given stronger information earlier. The current U.S. label now includes meningioma-related language, including a warning to discontinue Depo-Provera CI if meningioma is diagnosed and to monitor patients for signs and symptoms of meningioma.

A meningioma is a tumor that forms in the membranes surrounding the brain and spinal cord. It is often described as benign, but that does not mean it is minor. A meningioma can still cause severe headaches, vision changes, seizures, hearing problems, balance problems, memory issues, personality changes, or other neurological symptoms, depending on where it is located and how large it becomes. Some patients require surgery, radiation, ongoing scans, or long-term follow-up care. The seriousness of the injury depends on the individual patient, not just the pathology label.

There is published scientific literature that has drawn major attention to the issue. A 2024 BMJ study reported that prolonged use of medroxyprogesterone acetate was associated with increased risk of intracranial meningioma, and a 2025 U.S.-based study published in JAMA Neurology also reported an increased relative risk for women using depot medroxyprogesterone acetate, particularly with prolonged exposure. Those studies do not automatically prove every individual lawsuit, but they are part of the scientific and regulatory landscape surrounding these claims.

Yes. In December 2025, the FDA approved a labeling supplement that added information related to meningioma risk to the warnings and precautions section and to patient counseling information. The updated prescribing information states that Depo-Provera CI should be discontinued if meningioma is diagnosed and that patients should be monitored for signs and symptoms of meningioma.

MDL 3140 is the federal multidistrict litigation for Depo-Provera products liability cases. It is formally titled In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation and is centralized in the Northern District of Florida before Judge M. Casey Rodgers. An MDL is not the same as a class action. It is a coordinated federal proceeding for shared pretrial issues, while each plaintiff still keeps an individual claim. As of the JPML report dated February 2, 2026, 2,098 actions were pending in MDL 3140.

Possibly, yes. Many meningiomas are not malignant, but they can still be life-changing. If a tumor caused surgery, radiation, missed work, long-term symptoms, neurological deficits, recurring scans, or major disruption to daily life, those facts matter. A so-called benign tumor inside the skull can still produce devastating harm.

Not necessarily. Surgery can strengthen a damages presentation in some cases because it clearly shows the seriousness of the condition, but not every viable case requires brain surgery. Women who have documented meningioma diagnoses, meaningful symptoms, monitoring, radiation, or other measurable harm may still have claims worth evaluating.

There is no single universal rule. Duration of use matters, and longer exposure may be especially important in both medical and legal analysis, but each case depends on records, timing, diagnosis details, and the law that applies. Some cases may involve repeated injections over years, while others raise questions about shorter but still significant use.

Useful evidence often includes prescribing records, proof of injections, pharmacy records, OB-GYN or primary care records, MRI or CT reports, neurology records, neurosurgery records, pathology reports, radiation records, employment records showing lost income, and personal evidence showing how the diagnosis changed day-to-day life. A strong case usually begins with a precise timeline of exposure, symptoms, diagnosis, and treatment.

That depends on the facts of the case. Potential damages may include medical expenses, future care costs, lost wages, reduced earning capacity, pain and suffering, emotional distress, and damages tied to permanent impairment or reduced quality of life. In some cases, wrongful death claims may also be investigated. No ethical attorney should promise a result or quote a settlement number without a careful review.

Yes. Statutes of limitation and other timing rules may apply, and those deadlines can vary depending on the facts and the law governing the claim. Anyone considering a Depo-Provera meningioma lawsuit should speak with counsel promptly so records can be preserved and timing issues analyzed.

We believe women deserve real answers, not recycled mass-tort language. Our approach is grounded in serious injury advocacy, careful case review, respectful communication, and a willingness to explain difficult legal issues in plain English. If you contact our firm, we can review your history, discuss the current state of the litigation, and help you understand whether your case appears to fit the kinds of claims being pursued nationwide.